Relmada Therapeutics (RLMD) Interest Expenses (2014 - 2015)
Relmada Therapeutics (RLMD) reported Interest Expenses of $1172.0 for Q4 2015, up 6.74% year-over-year from $1098.0 in Q4 2014, and down 28.62% on a QoQ basis from $1642.0 in Q3 2015.
Relmada Therapeutics (RLMD) has 2 years of Interest Expenses data on file, last reported at $1172.0 in Q4 2015.
- Quarterly Interest Expenses rose 6.74% year-over-year to $1172.0 in Q4 2015, while the trailing twelve-month figure through Sep 2016 was $1172.0 (down 64.44% YoY) and the FY2015 annual result came in at $4922.0, up 100.8% from the prior year.
- Interest Expenses fell to $1172.0 in Q4 2015 per RLMD's latest filing, from $1642.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $435611.0 in Q2 2014 and bottomed at $125.0 in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1,172.00 |
| Dec 31, 2015 | 1,172.00 |
| Sep 30, 2015 | 1,642.00 |
| Sep 30, 2015 | 1,642.00 |
| Jun 30, 2015 | 431.00 |
| Jun 30, 2015 | 431.00 |
| Mar 31, 2015 | 125.00 |
| Mar 31, 2015 | 125.00 |
| Dec 31, 2014 | 1,098.00 |
| Dec 31, 2014 | 1,098.00 |
| Sep 30, 2014 | 3,268.00 |
| Sep 30, 2014 | 3,268.00 |
| Jun 30, 2014 | 435,611.00 |
| Jun 30, 2014 | 435,611.00 |
| Mar 31, 2014 | 123,800.00 |
| Mar 31, 2014 | 123,800.00 |